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Abstract 
Background: Many patients with brain metastases undergoing whole brain radiotherapy (WBRT) 
have very limited survival. The purpose of this study was to validate a nomogram derived from a 
large American database and to examine its ability to better predict short survival (cut-off 2 
months) than previous models. 
Material and Methods: This retrospective study included 254 European patients treated with 
primary WBRT. In addition, an exploratory analysis of patients managed with best supportive care 
(BSC) was performed too.  
Results: Median survival after WBRT was 3.0 months. The median nomogram point sum was 122 
(range 31-212). The nomogram-predicted median survival for a patient with 122 points is 3.3 
months. Despite the nomogram’s ability to stratify the patients into different prognostic groups, 
the survival curves of patients with intermediate point sum in the range of 90-139 points were 
largely superimposable. The poorest prognostic group with ≥180 points had a median and 
maximum survival of 1.8 and 4.6 months, respectively. Among these 18 patients (7%) 9 survived for 
less than and 9 for more than 2 months. Comparable survival outcomes were observed after BSC 
in a smaller group of 8 patients with ≥180 points.  
Conclusions: Because of several differences between the original and validation findings, the 
nomogram should be examined in additional large databases. Its ability to predict poor survival is 
promising and possibly comparable to our previously published models. The final goal of 
developing a validated model that allows poor prognosis patients to safely forego WBRT without 
compromising survival or quality of life requires further research efforts. 
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Introduction 
Development of better local and systemic 
treatment approaches has resulted in individually 
tailored management of patients with parenchymal 
brain metastases from solid extracranial primary 
tumors [1]. High local control rates and preservation 
of neurocognitive function can be achieved with 
stereotactic radiotherapy and surgical resection [2]. 
These recent developments have led to a decrease in 
the prescription of primary whole brain radiotherapy 
(WBRT). Fewer and fewer patients with favorable 
prognostic features are now being treated with 








approach [3]. However, it is a matter of debate 
whether or not WBRT should be offered to patients 
with adverse prognostic factors [4]. Their survival is 
often limited to few weeks, and therefore best 
supportive care (BSC) might also be an option. The 
challenge is, however, to predict who is in this 
subgroup. Previous attempts to use prognostic scores, 
such as the recursive partitioning analysis (RPA) [5] 
or graded prognostic assessment (GPA) [6], to select 
patients appropriate for BSC were not successful [7, 
8]. Even within the poor prognosis group of the RPA 
or diagnosis-specific (DS) GPA survival was 
heterogeneous. Thus, clinicians are afraid to withhold 
local therapy to patients who may experience 
prolonged survival when local measures lead to, at 
least temporary, control of the brain metastases. A 
disadvantage of this practice is overtreatment of 
patients with short survival, resulting in the fact that 
they often spend a large part of the remaining life 
span on active treatment [9] instead of spending time 
with their beloved ones.  
Barnholtz-Sloan et al. [10] developed a 
nomogram for individualized estimation of overall 
survival from the Radiation Therapy Oncology 
Group’s (RTOG) randomized trials [10]. The overall 
median survival in this large study with more than 
2000 patients was 136 days (4.5 months). Table 1 
shows the baseline characteristics that contributed to 
the nomogram. They were a mixture of the prognostic 
factors that also were part of the RPA, GPA and 
DS-GPA. In this model, the use of the nomogram 
results in a total point sum that corresponds to a 
certain predicted median, 6-month and 12-month 
survival probability. The purpose of the present study 
was to validate the nomogram in a European patient 
population and to examine its ability to predict short 
time survival better than the models previously tested 
by our group. We used identical methods and 
definitions as in our previous studies, e.g. for short 
survival (max. 2 months) [7].  
 
Table 1. Baseline characteristics included in the nomogram 
(Barnholtz-Sloan et al. 2012 [8])  
Parameter Also included in the RPA and 
DS-GPA 
Primary tumor site and histology no yes 
Status of primary disease 
(controlled/uncontrolled) 
yes no 
Metastatic spread (brain alone/other sides) yes yes 
Age yes yes  
Karnofsky performance status yes yes 
Number of brain lesions (single/multiple) no yes 
RPA: recursive partitioning analysis 
DS-GPA: diagnosis-specific graded prognostic assessment 
Material and Methods 
Patients and treatment 
This retrospective intention-to-treat study 
included 254 consecutive patients with brain 
metastases from common primary tumors included in 
the DS-GPA model (breast, lung, kidney, 
gastrointestinal cancer and malignant melanoma) 
who received palliative WBRT as primary treatment. 
Total doses in the range of 20-40 Gy were prescribed. 
The number of fractions ranged from 5-20. Patients 
who failed to complete all fractions of WBRT were 
also included. Since the main endpoint was short time 
survival, patients treated with upfront resection or 
stereotactic radiotherapy were not included, as those 
were supposed to have a superior prognosis. Most 
institutions reserve aggressive local management for 
patients considered to have better prognosis. The 
patients were treated between 2006 and 2015 and 
identified from a previously described prospectively 
maintained database [11], which included data from 
the radiotherapy centers in Bodø and Freiburg. 
Second line surgery or stereotactic radiotherapy for 
failure after WBRT was not an exclusion criterion. 
Systemic treatment was given according to local 
standards at the discretion of the medical oncologists. 
Prognosis was calculated according to the RPA, 
DS-GPA and nomogram as described in the original 
publications [5, 6, 10].  
Statistical methods 
Actuarial survival from the first day of 
radiotherapy was calculated employing the 
Kaplan-Meier method, and different groups were 
compared using the log-rank test (SPSS 22, IBM Corp., 
Armonk, NY, USA). Nine patients were alive at last 
follow-up (May 15, 2016). The median follow-up was 
22 months (range 4-84). Date of death was known in 
all other patients.  
Results 
Patient characteristics 
The median age was 64 years (range 24-93). The 
median Karnofsky performance status (KPS) was 70 
(range 30-100). Ninety-nine patients (39%) had less 
than four brain metastases. A controlled primary 
tumor was present in 164 patients (65%). However 220 
had extracranial metastases (87%). Eighty-eight 
patients (35%) had non-small cell lung and 61 (24%) 
breast cancer. Further patient characteristics are 
shown in Table 2. According to the RPA score, 10 
patients (4%) had a favorable, 150 (59%) an 
intermediate, and 94 (37%) an unfavorable prognosis. 
According to the 4-tiered DS-GPA model, 9 patients 




(3%) were in the best, 34 (13%) in the second best, 64 
(25%) in the second worst, and 146 (57%) in the worst 
prognostic group. The median DS-GPA point sum 
was 1.0.  
 
Table 2. Primary tumor type and nomogram point sum 
Primary n Median sum 
(range) 
Median survival in 
months 
Breast cancer 61 83 (31-131) 4.0 
NSCLC, 
adenocarcinoma 
62 119 (47-192) 3.5 
NSCLC, squamous cell 
carcinoma 
14 179.5 (135-201) 2.4 
NSCLC, large cell 
carcinoma 
12 135.5 (73-206)  2.1 
SCLC 27 147.5 (54-200) 3.2 
Malignant melanoma 35 140 (74-202) 3.0 
Gastrointestinal tumor* 26 146.5 (79-212) 2.0 
Kidney cancer 17 139 (102-165) 2.6 
NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer 
*mainly colorectal and esophageal cancer 
 
RPA and DS-GPA 
Both scores predicted survival. According to the 
three-tiered RPA, median survival was 5.6, 3.8 and 1.9 
months (p<0.0001, log-rank test pooled over all 
strata). In class III 6-month and 12-month survival 
rates were 12 and 4%, respectively. According to the 
four-tiered DS-GPA, median survival was 16.4, 4.5, 3.5 
and 2.5 months (p<0.0001, log-rank test pooled over 
all strata). In class IV 6-month and 12-month survival 
rates were 17 and 8%, respectively. 
Nomogram and survival 
The median nomogram point sum was 122 
(range 31-212, 25th percentile 94, 75th percentile 151). 
The median survival was 3.0 months (95% confidence 
interval 2.6-3.4 months). The nomogram-predicted 
median survival for a patient with 122 points is 100 
days (3.3 months). Table 3 shows survival outcomes 
for different prognostic groups with median survival 
ranging from 1.8 to 14.8 months for the extreme strata, 
defined as a point sum of <70 points and ≥180 points, 
respectively (p<0.0001, log-rank test pooled over all 
strata). Despite this ability to stratify the patients into 
different prognostic groups, the survival curves of 
patients with intermediate point sum, especially in 
the range of 90-139 points, were superimposable, as 
already suggested by the data shown in Table 3. 
Figure 1 shows the comparison of our own and RTOG 
database-derived survival outcomes. For many of the 
strata, minimal differences were observed. The 
poorest prognostic group with ≥180 points had a 
median and maximum survival of 1.8 and 4.6 months, 
respectively. Among these 18 patients (7%), 9 
survived for less than and 9 for more than 2 months. 
We observed survival of less than 2 months in one 
patient with point sum <70 (1/21, 5%), three patients 
with point sum 70-79 (3/16, 19%), and four patients 
with point sum 80-89 (4/17, 24%).  
 
Table 3. Survival outcomes stratified by nomogram point sum 
(p<0.0001, log-rank test pooled over all strata) 
Point 
sum 






<70 21 14.8 71% 52% 
70-79 16 3.1 38% 19% 
80-89 17 3.5 41% 12% 
90-99 23 4.0 24% 9% 
100-109 24 3.1 25% 8% 
110-119 21 3.6 24% 13% 
120-129 23 2.6 22% 17% 
130-139 20 3.0 30% 25% 
140-149 23 2.4 22% 13% 
150-159 25 2.0 24% 4% 
160-169 13 2.5 15% 0% 
170-179 10 2.8 0% 0% 
≥180 18 1.8 0% 0% 
 
Best supportive care (BSC) 
Our brain metastasis database contained 51 
patients managed with BSC who had complete 
information to calculate the nomogram point sum. 
Eight of these (16%) had a point sum ≥180. Median 
and maximum survival were 1.6 and 4.2 months, 
respectively. Four of them survived for more than 2 
months.  
Discussion 
We performed a retrospective validation study 
of the nomogram developed by Barnholtz-Sloan et al. 
[10] in a European patient population and examined 
the nomogram’s ability to predict short time survival 
better than previous models tested by our group [7, 8]. 
The study population consisted mainly of patients 
with intermediate or poor prognosis who were judged 
not to be appropriate candidates for aggressive local 
therapies, such as surgery or stereotactic 
radiotherapy. In the RTOG database, a small minority 
of resected or radiosurgically treated patients were 
included, e.g., participants in RTOG trial 95-08, while 
the vast majority was treated with primary palliative 
WBRT [10]. In addition, 57% of our patients belonged 
to the worst prognostic DS-GPA group, compared to 
11% in the original study. This discrepancy likely 
explains why the median survival in our study was 
only 3.0 months, while the RTOG patients survived 
for a median of 4.5 months. The prognostic impact of 
both RPA and DS-GPA could be confirmed in our 
study.  





Figure 1. Median survival of patients with different point sums in the RTOG and own database 
 
Limitations of this study include the number of 
patients, statistical power of subgroup analyses, and 
retrospective design. Whereas the number of patients 
was limited in our study database, they represent the 
total cohort of the two radiotherapy departments and 
consequently express the daily practice at these units. 
It is possible that the nomogram results would have 
matched the RTOG database findings even closer in a 
larger cohort of patients. However, we could confirm 
that the nomogram predicts especially favorable and 
unfavorable survival with high accuracy. A certain 
proportion of false positive and false negative 
findings is a known drawback of essentially all 
predictive tools available in the field of oncology 
[12-15]. For patients with a point sum in the order of 
90-139 points, no clear survival differences emerged. 
It is therefore necessary to examine the nomogram in 
additional databases.  
A secondary endpoint of our study was 
prediction of very short survival after WBRT. In the 
terminal phase of cancer progression, many patients 
might not survive long enough to experience the 
beneficial effects of radiotherapy [16]. Disadvantages 
to patients and family members, such as acute side 
effects, travel distance and out-of-pocket costs, must 
also be considered. Similarly, unnecessary use of 
specialized health care resources (e.g., radiotherapy) 
should be kept in mind as such resources may be 
allocated to other patients and waiting lists may 
consequently be further minimized. It would 
therefore be desirable to avoid fruitless WBRT in 
patients who may experience the same survival and 
quality of life with optimal BSC. We have previously 
reported that patients with a DS-GPA score of 0-1.5 
points and age ≥75 years or KPS ≤50 or uncontrolled 
primary tumor with extracranial metastases to at least 
two organs might be appropriate candidates for BSC 
[7]. A follow-up study suggested that patients with a 
combination of three new adverse features (elevated 
serum lactate dehydrogenase plus low albumin plus 
extracranial metastases to at least two organs) might 
also be considered for BSC [17]. We hoped that the 
nomogram could be an even better tool, as it is easy to 
handle and accurate enough to predict short survival 
of 2 months or less. However, even among those 7% of 
patients with the highest point sums (≥180), 50% 
survived for 2-4.6 months. Our BSC database was too 
small to create a sufficiently large group of patients 
with ≥180 points managed without WBRT. However, 
it was interesting to note, from this exploratory 
analysis, that the small group of 8 patients had 
survival outcomes that resembled those of their 
WBRT counterparts very closely. Despite the 
promising potential of the nomogram, our previous 
recommendations for patient selection will remain 
unaltered until larger studies have confirmed that 
WBRT and BSC result in undistinguishable outcomes. 
As already realized in the RPA studies [5], 
patients with poor KPS (RPA class 3) are a 
heterogeneous group. Despite short median survival, 
post-treatment functional improvement is possible 
and might even be associated with survival beyond 12 
months. Lee et al. have also reported that RPA class 3 
patients who presented with hemiparesis, cognitive 
deficit or apraxia could respond to palliative 
radiotherapy with the potential to benefit from 




progression-free survival of 12 months or more [18], a 
finding in line with the authors’ personal experience. 
In a prospective randomized phase II study WBRT 
was associated with improvements in cognitive and 
emotional function but also with worsened nausea 
[19]. Complete and partial imaging response rate was 
55%. In a different study, a total of 14 symptom scores 
and overall quality of life were collected prospectively 
in 217 patients for up to 3 months [20]. Appetite loss, 
weakness, and nausea significantly increased from 
baseline, while balance, headache, and anxiety 
significantly decreased from baseline. Clearly, quality 
of life is a complex endpoint, which is influenced by 
extracranial disease extent and also side effects of 
systemic therapy. This endpoint has not been 
evaluated in our study. In general, important goals for 
the treatment of brain metastases include alleviating 
neurological symptoms, preventing their progression 
and neurological deterioration, and thus enhancing 
quality of life. Treatment decisions should not be 
based on life expectancy alone. 
Conclusions 
Because of several differences between RTOG 
database and present results, the nomogram should 
be examined in additional large studies. Despite its 
general ability to predict long and short time survival, 
our previous models for poor prognosis patients 
appear preferable because they were derived from 
larger subgroups. The final goal of developing a 
validated model that allows patients with adverse 
prognostic features to safely forego WBRT without 
compromising survival, symptom control and quality 
of life requires further research efforts. 
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